{"gene":"RIN3","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":2003,"finding":"RIN3 acts as a guanine nucleotide exchange factor (GEF) for Rab5, stimulating and stabilizing GTP-bound Rab5 in cell-free and cell-based assays. RIN3 localizes to cytoplasmic vesicles containing Rab5 but not EEA1, and transferrin is partly transported through RIN3-positive vesicles to early endosomes.","method":"Cell-free GEF activity assay, immunofluorescence co-localization, transferrin trafficking assay in HeLa cells","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical GEF assay plus cell-based localization and trafficking, founding study replicated by subsequent work","pmids":["12972505"],"is_preprint":false},{"year":2003,"finding":"RIN3 interacts with amphiphysin II (BIN2/AMPH2) via its proline-rich domain binding the amphiphysin SH3 domain; co-expression causes cytoplasmic amphiphysin II to translocate into RIN3- and Rab5-positive vesicles.","method":"Co-immunoprecipitation, domain mapping, co-expression/co-localization in HeLa cells","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal interaction demonstrated by pulldown/Co-IP with domain mapping in a single lab","pmids":["12972505"],"is_preprint":false},{"year":2008,"finding":"Tyrosine phosphorylation signals (induced by pervanadate) translocate RIN3 from the cytoplasm to Rab5-positive vesicles. Mutational analysis indicates an activated Ras GTPase interacts with the inhibitory RA domain, promoting an active conformation, while the RIN-unique RH domain constitutes a Rab5-binding region required for GEF action.","method":"Pervanadate treatment of HeLa cells, domain-deletion mutagenesis, immunofluorescence","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis with defined domain dissection in a single lab","pmids":["18486601"],"is_preprint":false},{"year":2011,"finding":"RIN3 acts as a GEF specifically for Rab31 (a Rab5 subfamily member) in addition to Rab5; it forms enlarged vesicles and tubular structures co-labeled with Rab31. Serine-to-alanine substitutions between the SH2 and RH domains selectively abolish GEF activity toward Rab31 but not Rab5.","method":"Cell-free and cell-based GEF activity assays, site-directed mutagenesis, immunofluorescence co-localization in HeLa cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro GEF assay combined with mutagenesis and cell-based morphological readout in a single rigorous study","pmids":["21586568"],"is_preprint":false},{"year":2011,"finding":"RIN3's Rab31-GEF activity is required for partial redistribution of the cation-dependent mannose 6-phosphate receptor (CD-MPR) from the trans-Golgi network to peripheral vesicles.","method":"Immunofluorescence imaging of CD-MPR localization combined with RIN3 Rab31-GEF-deficient mutant expression in HeLa cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional readout tied to specific mutant, single lab","pmids":["21586568"],"is_preprint":false},{"year":2012,"finding":"In mast cells, RIN3 functions downstream of KIT/SCF signaling as a Rab5-GEF; SCF stimulation increases GTP-Rab5 levels proportional to RIN3 expression and causes dissociation of a pre-formed RIN3–BIN2 complex. RIN3 silencing accelerates SCF-induced KIT internalization, while RIN3 overexpression leads to KIT downregulation, establishing RIN3 as a negative regulator of KIT endocytosis and mast cell migration.","method":"RIN3 knockdown/overexpression, GTP-Rab5 pull-down assay, KIT internalization assay, mast cell migration assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (GEF assay, KD, OE, migration assay) with clear mechanistic pathway placement","pmids":["23185384"],"is_preprint":false},{"year":2015,"finding":"CD2AP SH3 domains 1 and 2 directly bind two proline-rich epitopes on RIN3 (with SH3-3 non-functional in precipitation). RIN3 recruits CD2AP to RAB5a-positive early endosomes via these interaction sites. Crystal structures of CD2AP SH3-1 and SH3-2 in complex with RIN3 epitopes were solved at 1.65 Å and 1.11 Å resolution, defining the molecular basis of the interaction.","method":"Peptide array screening, Co-IP/pulldown, isothermal titration calorimetry, X-ray crystallography, immunofluorescence co-localization","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures at high resolution combined with ITC and Co-IP in a single rigorous study","pmids":["26296892"],"is_preprint":false},{"year":2020,"finding":"Via its proline-rich domain, RIN3 recruits BIN1 and CD2AP to early endosomes. Overexpression of RIN3 promotes APP cleavage (increased CTFs) and increases phosphorylated Tau levels; effects are rescued by dominant-negative Rab5 (Rab5-S34N), placing RIN3 upstream of Rab5 in this pathway.","method":"Co-immunoprecipitation, mass spectrometry interactomics, yeast two-hybrid, immunofluorescence, APP CTF western blot, live imaging of axonal transport, dominant-negative Rab5 rescue in PC12 and primary BFCNs","journal":"Translational neurodegeneration","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (MS, Co-IP, Y2H, genetic rescue) across neuronal models establishing pathway position","pmids":["32552912"],"is_preprint":false},{"year":2021,"finding":"Targeted inactivation of mouse Rin3 (Rin3-/- knockout) increases trabecular bone mass by reducing osteoclast surface at 8 weeks, establishing that Rin3 negatively regulates bone resorption in vivo. At 52 weeks, increased bone formation markers were also observed.","method":"Constitutive Rin3 knockout mice, micro-CT, bone histomorphometry","journal":"Calcified tissue international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO with quantitative histomorphometric readout, single lab, no molecular mechanism","pmids":["33725152"],"is_preprint":false},{"year":2022,"finding":"RIN3 differentially regulates recruitment of neuronal BIN1V1 and non-neuronal BIN1V9 into RAB5-positive endosomes. BIN1V1, but not BIN1V9, delays APP (but not BACE1) endocytosis into early endosomes in a RIN3-dependent manner, spatially separating APP and BACE1 and reducing Aβ generation. RIN3 sequesters BIN1V1 in RAB5-positive endosomes likely via the CLAP domain.","method":"Confocal microscopy, FACS-based cell enrichment, Aβ ELISA, biotinylated APP internalization assay, western blot for APP processing","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (internalization assay, ELISA, imaging, western) with isoform-specific controls establishing mechanistic pathway","pmids":["35241726"],"is_preprint":false},{"year":2026,"finding":"Disruption of BIN1–RIN3 binding—either by Rin3 constitutive knockout or by CRISPR-engineered familial AD RIN3 missense mutations in the BIN1-binding domain of human iPSC-derived neurons—leads to RAB5 hyperactivation and enlargement of neuronal endosomes. BIN1 is established as a critical negative regulator of RIN3-driven RAB5 activation and endosomal homeostasis.","method":"Rin3 constitutive knockout mice, CRISPR-Cas9 editing of human iPSC-derived neurons, RAB5 activation assays, endosome size quantification, transcriptomic profiling","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic loss-of-function in two independent model systems (mouse KO and human iPSC neurons) with direct RAB5 activity measurement and morphological readouts","pmids":["41604486"],"is_preprint":false}],"current_model":"RIN3 is a multidomain Rab5/Rab31 guanine nucleotide exchange factor that, upon activation by tyrosine-phosphorylation–induced Ras engagement with its RA domain, localizes to early endocytic vesicles where it activates RAB5 to drive membrane trafficking; it interacts via its proline-rich domain with SH3-containing proteins BIN1 and CD2AP to recruit them to RAB5-positive endosomes, with BIN1 serving as a critical brake on RIN3-driven RAB5 hyperactivation, and in neuronal and immune cell contexts RIN3 regulates APP endocytosis and Aβ generation, KIT internalization in mast cells, and osteoclast-mediated bone resorption."},"narrative":{"mechanistic_narrative":"RIN3 is a multidomain guanine nucleotide exchange factor (GEF) that activates the early-endosomal small GTPases RAB5 and RAB31 to drive membrane trafficking [PMID:12972505, PMID:21586568]. It localizes to cytoplasmic RAB5-positive vesicles distinct from EEA1 compartments and routes a portion of internalized transferrin to early endosomes [PMID:12972505], with its RIN-unique RH domain forming the RAB5-binding region required for catalysis [PMID:18486601]. RIN3 activity is gated by upstream signaling: tyrosine-phosphorylation events translocate RIN3 to RAB5-positive vesicles, and engagement of activated Ras with its inhibitory RA domain promotes the active conformation [PMID:18486601]. Its Rab31-GEF activity, which is genetically separable from its Rab5-GEF function, supports redistribution of the cation-dependent mannose-6-phosphate receptor from the trans-Golgi network to peripheral vesicles [PMID:21586568]. Through its proline-rich domain, RIN3 binds the SH3 domains of the endocytic adaptors BIN1/amphiphysin and CD2AP and recruits them onto RAB5-positive endosomes [PMID:12972505, PMID:26296892, PMID:32552912], with high-resolution structures defining the CD2AP SH3-1/SH3-2 docking sites [PMID:26296892]; BIN1 acts as a critical brake whose loss—via Rin3 knockout or familial Alzheimer's disease RIN3 missense mutations in the BIN1-binding domain—causes RAB5 hyperactivation and endosomal enlargement [PMID:41604486]. In specialized cell contexts RIN3 operates downstream of KIT/SCF signaling as a negative regulator of KIT endocytosis and mast cell migration [PMID:23185384], modulates APP endocytosis and amyloid-β generation by sequestering the neuronal BIN1V1 isoform to spatially separate APP from BACE1 [PMID:32552912, PMID:35241726], and negatively regulates osteoclast-mediated bone resorption in vivo [PMID:33725152].","teleology":[{"year":2003,"claim":"Established RIN3's core biochemical identity by showing it is a GEF that loads and stabilizes GTP onto Rab5 and resides on a distinct early-endocytic vesicle population, defining it as a trafficking regulator.","evidence":"Cell-free GEF assay, immunofluorescence co-localization, and transferrin trafficking in HeLa cells","pmids":["12972505"],"confidence":"High","gaps":["Did not define how RIN3 GEF activity is regulated in cells","RAB5 effector consequences downstream of activation not addressed"]},{"year":2003,"claim":"Identified the first SH3-domain partner, showing RIN3's proline-rich domain recruits amphiphysin II onto RIN3/Rab5 vesicles and linking RIN3 to the endocytic adaptor machinery.","evidence":"Co-IP, domain mapping, and co-expression/co-localization in HeLa cells","pmids":["12972505"],"confidence":"Medium","gaps":["Functional consequence of amphiphysin recruitment not established","Single-lab interaction without orthogonal binding affinity measurement"]},{"year":2008,"claim":"Defined the activation logic of RIN3, showing tyrosine-phosphorylation triggers vesicular translocation and that Ras engagement with the inhibitory RA domain relieves autoinhibition while the RH domain mediates Rab5 binding.","evidence":"Pervanadate treatment and domain-deletion mutagenesis with immunofluorescence in HeLa cells","pmids":["18486601"],"confidence":"Medium","gaps":["Direct kinase responsible for RIN3 phosphorylation not identified","Physiological upstream signal in native cells not demonstrated"]},{"year":2011,"claim":"Expanded RIN3 substrate range to Rab31 and demonstrated catalytic separability, showing distinct residues control Rab31 versus Rab5 activation and that Rab31-GEF activity drives CD-MPR redistribution from the TGN.","evidence":"Cell-free and cell-based GEF assays, site-directed mutagenesis, and CD-MPR imaging in HeLa cells","pmids":["21586568"],"confidence":"High","gaps":["Physiological context distinguishing Rab5 versus Rab31 usage unclear","CD-MPR cargo consequence (e.g., lysosomal enzyme sorting) not measured"]},{"year":2012,"claim":"Placed RIN3 in a receptor signaling pathway, showing it acts downstream of KIT/SCF as a Rab5-GEF and negatively regulates KIT internalization and mast cell migration.","evidence":"RIN3 knockdown/overexpression, GTP-Rab5 pull-down, KIT internalization and migration assays in mast cells","pmids":["23185384"],"confidence":"High","gaps":["Mechanism linking RIN3-BIN2 dissociation to KIT trafficking not fully resolved","Whether Rab31 contributes in this context untested"]},{"year":2015,"claim":"Resolved the molecular basis of RIN3 adaptor recruitment, mapping two proline-rich epitopes to CD2AP SH3-1/SH3-2 at atomic resolution and showing RIN3 recruits CD2AP to RAB5a endosomes.","evidence":"Peptide array, Co-IP, ITC, X-ray crystallography (1.65 Å, 1.11 Å), and co-localization","pmids":["26296892"],"confidence":"High","gaps":["Functional role of CD2AP recruitment in trafficking not established","Competition between CD2AP and BIN1 for RIN3 not examined"]},{"year":2020,"claim":"Linked RIN3 to neurodegeneration-relevant trafficking, showing RIN3 recruits BIN1 and CD2AP to endosomes and promotes APP cleavage and Tau phosphorylation through a Rab5-dependent pathway.","evidence":"Co-IP, MS interactomics, Y2H, APP CTF western, axonal transport imaging, and dominant-negative Rab5 rescue in PC12 and primary BFCNs","pmids":["32552912"],"confidence":"High","gaps":["Direct mechanism connecting Rab5 activation to APP processing not detailed","In vivo relevance to disease not yet tested at this stage"]},{"year":2022,"claim":"Defined isoform-specific control of amyloidogenesis, showing RIN3 sequesters neuronal BIN1V1 to delay APP (not BACE1) endocytosis, spatially separating the two and reducing Aβ generation.","evidence":"Confocal microscopy, FACS enrichment, Aβ ELISA, biotinylated APP internalization, and APP processing western blots","pmids":["35241726"],"confidence":"High","gaps":["Precise CLAP-domain contribution to sequestration not biochemically proven","Generalizability beyond the studied neuronal model unaddressed"]},{"year":2021,"claim":"Provided in vivo loss-of-function evidence that RIN3 negatively regulates bone resorption, showing Rin3 knockout increases trabecular bone mass via reduced osteoclast surface.","evidence":"Constitutive Rin3 knockout mice, micro-CT, and bone histomorphometry","pmids":["33725152"],"confidence":"Medium","gaps":["Molecular mechanism in osteoclasts not defined","Whether the effect is cell-autonomous to osteoclasts not resolved"]},{"year":2026,"claim":"Established BIN1 as the critical brake on RIN3 and connected RIN3 to familial Alzheimer's disease, showing that disrupting BIN1-RIN3 binding by knockout or AD missense mutations causes RAB5 hyperactivation and endosomal enlargement.","evidence":"Rin3 knockout mice, CRISPR-edited human iPSC-derived neurons, RAB5 activation assays, endosome size quantification, and transcriptomics","pmids":["41604486"],"confidence":"High","gaps":["Structural basis of how BIN1 binding suppresses GEF activity not resolved","Downstream consequences of RAB5 hyperactivation on neuronal survival not fully mapped"]},{"year":null,"claim":"How RIN3's distinct interactions and GEF activities (Rab5 vs Rab31; BIN1 vs CD2AP vs amphiphysin) are coordinately switched across cell types and signaling states remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No integrated structural model of the autoinhibited versus activated full-length protein","Identity of the physiological kinase activating RIN3 unknown","Quantitative rules governing partner selection at the endosome undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,3,5]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[1,6,7]}],"localization":[{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[0,1]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[6,7,9,10]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,2]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[0,3,5]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,5]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,9,10]}],"complexes":[],"partners":["BIN1","CD2AP","RAB5","RAB31","AMPH2","KIT","RAS"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8TB24","full_name":"Ras and Rab interactor 3","aliases":["Ras interaction/interference protein 3"],"length_aa":985,"mass_kda":107.9,"function":"Ras effector protein that functions as a guanine nucleotide exchange (GEF) for RAB5B and RAB31, by exchanging bound GDP for free GTP. Required for normal RAB31 function","subcellular_location":"Cytoplasm; Cytoplasmic vesicle; Early endosome","url":"https://www.uniprot.org/uniprotkb/Q8TB24/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RIN3","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"BIN1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/RIN3","total_profiled":1310},"omim":[{"mim_id":"610223","title":"RAS AND RAB INTERACTOR 3; RIN3","url":"https://www.omim.org/entry/610223"},{"mim_id":"605694","title":"RAS-ASSOCIATED PROTEIN RAB31; RAB31","url":"https://www.omim.org/entry/605694"},{"mim_id":"167250","title":"PAGET DISEASE OF BONE 3; PDB3","url":"https://www.omim.org/entry/167250"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":43.7}],"url":"https://www.proteinatlas.org/search/RIN3"},"hgnc":{"alias_symbol":["FLJ22439"],"prev_symbol":[]},"alphafold":{"accession":"Q8TB24","domains":[{"cath_id":"3.30.505.10","chopping":"53-186_221-225","consensus_level":"high","plddt":83.3334,"start":53,"end":225},{"cath_id":"-","chopping":"595-690","consensus_level":"high","plddt":85.7455,"start":595,"end":690},{"cath_id":"1.20.1050.80","chopping":"708-873","consensus_level":"high","plddt":84.9534,"start":708,"end":873},{"cath_id":"3.10.20.90","chopping":"879-966_974-985","consensus_level":"high","plddt":87.0054,"start":879,"end":985}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TB24","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TB24-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TB24-F1-predicted_aligned_error_v6.png","plddt_mean":61.41},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RIN3","jax_strain_url":"https://www.jax.org/strain/search?query=RIN3"},"sequence":{"accession":"Q8TB24","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8TB24.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8TB24/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TB24"}},"corpus_meta":[{"pmid":"12972505","id":"PMC_12972505","title":"RIN3: a novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway.","date":"2003","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/12972505","citation_count":136,"is_preprint":false},{"pmid":"32552912","id":"PMC_32552912","title":"Upregulation of RIN3 induces endosomal dysfunction in Alzheimer's disease.","date":"2020","source":"Translational neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/32552912","citation_count":54,"is_preprint":false},{"pmid":"21586568","id":"PMC_21586568","title":"Characterization of RIN3 as a guanine nucleotide exchange factor for the Rab5 subfamily GTPase Rab31.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21586568","citation_count":54,"is_preprint":false},{"pmid":"26296892","id":"PMC_26296892","title":"Differential Recognition Preferences of the Three Src Homology 3 (SH3) Domains from the Adaptor CD2-associated Protein (CD2AP) and Direct Association with Ras and Rab Interactor 3 (RIN3).","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26296892","citation_count":36,"is_preprint":false},{"pmid":"25701875","id":"PMC_25701875","title":"Targeted sequencing of the Paget's disease associated 14q32 locus identifies several missense coding variants in RIN3 that predispose to Paget's disease of bone.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25701875","citation_count":27,"is_preprint":false},{"pmid":"35241726","id":"PMC_35241726","title":"The neuronal-specific isoform of BIN1 regulates β-secretase cleavage of APP and Aβ generation in a RIN3-dependent manner.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35241726","citation_count":25,"is_preprint":false},{"pmid":"23185384","id":"PMC_23185384","title":"RIN3 is a negative regulator of mast cell responses to SCF.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23185384","citation_count":18,"is_preprint":false},{"pmid":"30480232","id":"PMC_30480232","title":"Methylation Profiling RIN3 and MEF2C Identifies Epigenetic Marks Associated with Sporadic Early Onset Alzheimer's Disease.","date":"2017","source":"Journal of Alzheimer's disease reports","url":"https://pubmed.ncbi.nlm.nih.gov/30480232","citation_count":18,"is_preprint":false},{"pmid":"18486601","id":"PMC_18486601","title":"Tyr-phosphorylation signals translocate RIN3, the small GTPase Rab5-GEF, to early endocytic vesicles.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18486601","citation_count":15,"is_preprint":false},{"pmid":"37995081","id":"PMC_37995081","title":"The Role of RIN3 Gene in Alzheimer's Disease Pathogenesis: a Comprehensive Review.","date":"2023","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/37995081","citation_count":11,"is_preprint":false},{"pmid":"34408420","id":"PMC_34408420","title":"Methylation of the RIN3 Promoter is Associated with Transient Ischemic Stroke/Mild Ischemic Stroke with Early Cognitive Impairment.","date":"2021","source":"Neuropsychiatric disease and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/34408420","citation_count":8,"is_preprint":false},{"pmid":"33725152","id":"PMC_33725152","title":"Targeted Inactivation of Rin3 Increases Trabecular Bone Mass by Reducing Bone Resorption and Favouring Bone Formation.","date":"2021","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/33725152","citation_count":7,"is_preprint":false},{"pmid":"30726512","id":"PMC_30726512","title":"Genetic Variation in RIN3 in the Belgian Population Supports Its Involvement in the Pathogenesis of Paget's Disease of Bone and Modifies the Age of Onset.","date":"2019","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/30726512","citation_count":6,"is_preprint":false},{"pmid":"39221227","id":"PMC_39221227","title":"Genome assemblies for Chromidotilapia guntheri (Teleostei: Cichlidae) identify a novel candidate gene for vertebrate sex determination, RIN3.","date":"2024","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39221227","citation_count":3,"is_preprint":false},{"pmid":"40078451","id":"PMC_40078451","title":"The Correlation Between RIN3 Gene Methylation and Cognitive Impairment in Parkinson's Disease.","date":"2025","source":"Neuropsychiatric disease and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/40078451","citation_count":2,"is_preprint":false},{"pmid":"41604486","id":"PMC_41604486","title":"RIN3 mutations impairing binding of the Alzheimer's disease-associated protein BIN1 lead to RAB5 hyperactivation and endosomal pathology.","date":"2026","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/41604486","citation_count":0,"is_preprint":false},{"pmid":"40693418","id":"PMC_40693418","title":"A panel incorporating genetic variants of RIN3, NLRC3, and SLX4 shows promise in predicting remission after tofacitinib therapy in rheumatoid arthritis patients.","date":"2025","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/40693418","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.01.25332822","title":"Genetically determined platelet traits impact stroke risk through multiple mechanisms and cell types","date":"2025-08-05","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.01.25332822","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.09.24318706","title":"Exploring genetic risk factors for pneumonia using biobank resources - Insights across subpopulations","date":"2024-12-10","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.09.24318706","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":13145,"output_tokens":2894,"usd":0.041423,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10143,"output_tokens":3793,"usd":0.07277,"stage2_stop_reason":"end_turn"},"total_usd":0.114193,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"RIN3 acts as a guanine nucleotide exchange factor (GEF) for Rab5, stimulating and stabilizing GTP-bound Rab5 in cell-free and cell-based assays. RIN3 localizes to cytoplasmic vesicles containing Rab5 but not EEA1, and transferrin is partly transported through RIN3-positive vesicles to early endosomes.\",\n      \"method\": \"Cell-free GEF activity assay, immunofluorescence co-localization, transferrin trafficking assay in HeLa cells\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical GEF assay plus cell-based localization and trafficking, founding study replicated by subsequent work\",\n      \"pmids\": [\"12972505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RIN3 interacts with amphiphysin II (BIN2/AMPH2) via its proline-rich domain binding the amphiphysin SH3 domain; co-expression causes cytoplasmic amphiphysin II to translocate into RIN3- and Rab5-positive vesicles.\",\n      \"method\": \"Co-immunoprecipitation, domain mapping, co-expression/co-localization in HeLa cells\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal interaction demonstrated by pulldown/Co-IP with domain mapping in a single lab\",\n      \"pmids\": [\"12972505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Tyrosine phosphorylation signals (induced by pervanadate) translocate RIN3 from the cytoplasm to Rab5-positive vesicles. Mutational analysis indicates an activated Ras GTPase interacts with the inhibitory RA domain, promoting an active conformation, while the RIN-unique RH domain constitutes a Rab5-binding region required for GEF action.\",\n      \"method\": \"Pervanadate treatment of HeLa cells, domain-deletion mutagenesis, immunofluorescence\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis with defined domain dissection in a single lab\",\n      \"pmids\": [\"18486601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RIN3 acts as a GEF specifically for Rab31 (a Rab5 subfamily member) in addition to Rab5; it forms enlarged vesicles and tubular structures co-labeled with Rab31. Serine-to-alanine substitutions between the SH2 and RH domains selectively abolish GEF activity toward Rab31 but not Rab5.\",\n      \"method\": \"Cell-free and cell-based GEF activity assays, site-directed mutagenesis, immunofluorescence co-localization in HeLa cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro GEF assay combined with mutagenesis and cell-based morphological readout in a single rigorous study\",\n      \"pmids\": [\"21586568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RIN3's Rab31-GEF activity is required for partial redistribution of the cation-dependent mannose 6-phosphate receptor (CD-MPR) from the trans-Golgi network to peripheral vesicles.\",\n      \"method\": \"Immunofluorescence imaging of CD-MPR localization combined with RIN3 Rab31-GEF-deficient mutant expression in HeLa cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional readout tied to specific mutant, single lab\",\n      \"pmids\": [\"21586568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In mast cells, RIN3 functions downstream of KIT/SCF signaling as a Rab5-GEF; SCF stimulation increases GTP-Rab5 levels proportional to RIN3 expression and causes dissociation of a pre-formed RIN3–BIN2 complex. RIN3 silencing accelerates SCF-induced KIT internalization, while RIN3 overexpression leads to KIT downregulation, establishing RIN3 as a negative regulator of KIT endocytosis and mast cell migration.\",\n      \"method\": \"RIN3 knockdown/overexpression, GTP-Rab5 pull-down assay, KIT internalization assay, mast cell migration assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (GEF assay, KD, OE, migration assay) with clear mechanistic pathway placement\",\n      \"pmids\": [\"23185384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CD2AP SH3 domains 1 and 2 directly bind two proline-rich epitopes on RIN3 (with SH3-3 non-functional in precipitation). RIN3 recruits CD2AP to RAB5a-positive early endosomes via these interaction sites. Crystal structures of CD2AP SH3-1 and SH3-2 in complex with RIN3 epitopes were solved at 1.65 Å and 1.11 Å resolution, defining the molecular basis of the interaction.\",\n      \"method\": \"Peptide array screening, Co-IP/pulldown, isothermal titration calorimetry, X-ray crystallography, immunofluorescence co-localization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures at high resolution combined with ITC and Co-IP in a single rigorous study\",\n      \"pmids\": [\"26296892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Via its proline-rich domain, RIN3 recruits BIN1 and CD2AP to early endosomes. Overexpression of RIN3 promotes APP cleavage (increased CTFs) and increases phosphorylated Tau levels; effects are rescued by dominant-negative Rab5 (Rab5-S34N), placing RIN3 upstream of Rab5 in this pathway.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry interactomics, yeast two-hybrid, immunofluorescence, APP CTF western blot, live imaging of axonal transport, dominant-negative Rab5 rescue in PC12 and primary BFCNs\",\n      \"journal\": \"Translational neurodegeneration\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (MS, Co-IP, Y2H, genetic rescue) across neuronal models establishing pathway position\",\n      \"pmids\": [\"32552912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Targeted inactivation of mouse Rin3 (Rin3-/- knockout) increases trabecular bone mass by reducing osteoclast surface at 8 weeks, establishing that Rin3 negatively regulates bone resorption in vivo. At 52 weeks, increased bone formation markers were also observed.\",\n      \"method\": \"Constitutive Rin3 knockout mice, micro-CT, bone histomorphometry\",\n      \"journal\": \"Calcified tissue international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with quantitative histomorphometric readout, single lab, no molecular mechanism\",\n      \"pmids\": [\"33725152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RIN3 differentially regulates recruitment of neuronal BIN1V1 and non-neuronal BIN1V9 into RAB5-positive endosomes. BIN1V1, but not BIN1V9, delays APP (but not BACE1) endocytosis into early endosomes in a RIN3-dependent manner, spatially separating APP and BACE1 and reducing Aβ generation. RIN3 sequesters BIN1V1 in RAB5-positive endosomes likely via the CLAP domain.\",\n      \"method\": \"Confocal microscopy, FACS-based cell enrichment, Aβ ELISA, biotinylated APP internalization assay, western blot for APP processing\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (internalization assay, ELISA, imaging, western) with isoform-specific controls establishing mechanistic pathway\",\n      \"pmids\": [\"35241726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Disruption of BIN1–RIN3 binding—either by Rin3 constitutive knockout or by CRISPR-engineered familial AD RIN3 missense mutations in the BIN1-binding domain of human iPSC-derived neurons—leads to RAB5 hyperactivation and enlargement of neuronal endosomes. BIN1 is established as a critical negative regulator of RIN3-driven RAB5 activation and endosomal homeostasis.\",\n      \"method\": \"Rin3 constitutive knockout mice, CRISPR-Cas9 editing of human iPSC-derived neurons, RAB5 activation assays, endosome size quantification, transcriptomic profiling\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic loss-of-function in two independent model systems (mouse KO and human iPSC neurons) with direct RAB5 activity measurement and morphological readouts\",\n      \"pmids\": [\"41604486\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RIN3 is a multidomain Rab5/Rab31 guanine nucleotide exchange factor that, upon activation by tyrosine-phosphorylation–induced Ras engagement with its RA domain, localizes to early endocytic vesicles where it activates RAB5 to drive membrane trafficking; it interacts via its proline-rich domain with SH3-containing proteins BIN1 and CD2AP to recruit them to RAB5-positive endosomes, with BIN1 serving as a critical brake on RIN3-driven RAB5 hyperactivation, and in neuronal and immune cell contexts RIN3 regulates APP endocytosis and Aβ generation, KIT internalization in mast cells, and osteoclast-mediated bone resorption.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RIN3 is a multidomain guanine nucleotide exchange factor (GEF) that activates the early-endosomal small GTPases RAB5 and RAB31 to drive membrane trafficking [#0, #3]. It localizes to cytoplasmic RAB5-positive vesicles distinct from EEA1 compartments and routes a portion of internalized transferrin to early endosomes [#0], with its RIN-unique RH domain forming the RAB5-binding region required for catalysis [#2]. RIN3 activity is gated by upstream signaling: tyrosine-phosphorylation events translocate RIN3 to RAB5-positive vesicles, and engagement of activated Ras with its inhibitory RA domain promotes the active conformation [#2]. Its Rab31-GEF activity, which is genetically separable from its Rab5-GEF function, supports redistribution of the cation-dependent mannose-6-phosphate receptor from the trans-Golgi network to peripheral vesicles [#3, #4]. Through its proline-rich domain, RIN3 binds the SH3 domains of the endocytic adaptors BIN1/amphiphysin and CD2AP and recruits them onto RAB5-positive endosomes [#1, #6, #7], with high-resolution structures defining the CD2AP SH3-1/SH3-2 docking sites [#6]; BIN1 acts as a critical brake whose loss—via Rin3 knockout or familial Alzheimer's disease RIN3 missense mutations in the BIN1-binding domain—causes RAB5 hyperactivation and endosomal enlargement [#10]. In specialized cell contexts RIN3 operates downstream of KIT/SCF signaling as a negative regulator of KIT endocytosis and mast cell migration [#5], modulates APP endocytosis and amyloid-β generation by sequestering the neuronal BIN1V1 isoform to spatially separate APP from BACE1 [#7, #9], and negatively regulates osteoclast-mediated bone resorption in vivo [#8].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established RIN3's core biochemical identity by showing it is a GEF that loads and stabilizes GTP onto Rab5 and resides on a distinct early-endocytic vesicle population, defining it as a trafficking regulator.\",\n      \"evidence\": \"Cell-free GEF assay, immunofluorescence co-localization, and transferrin trafficking in HeLa cells\",\n      \"pmids\": [\"12972505\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define how RIN3 GEF activity is regulated in cells\", \"RAB5 effector consequences downstream of activation not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified the first SH3-domain partner, showing RIN3's proline-rich domain recruits amphiphysin II onto RIN3/Rab5 vesicles and linking RIN3 to the endocytic adaptor machinery.\",\n      \"evidence\": \"Co-IP, domain mapping, and co-expression/co-localization in HeLa cells\",\n      \"pmids\": [\"12972505\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of amphiphysin recruitment not established\", \"Single-lab interaction without orthogonal binding affinity measurement\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined the activation logic of RIN3, showing tyrosine-phosphorylation triggers vesicular translocation and that Ras engagement with the inhibitory RA domain relieves autoinhibition while the RH domain mediates Rab5 binding.\",\n      \"evidence\": \"Pervanadate treatment and domain-deletion mutagenesis with immunofluorescence in HeLa cells\",\n      \"pmids\": [\"18486601\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct kinase responsible for RIN3 phosphorylation not identified\", \"Physiological upstream signal in native cells not demonstrated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Expanded RIN3 substrate range to Rab31 and demonstrated catalytic separability, showing distinct residues control Rab31 versus Rab5 activation and that Rab31-GEF activity drives CD-MPR redistribution from the TGN.\",\n      \"evidence\": \"Cell-free and cell-based GEF assays, site-directed mutagenesis, and CD-MPR imaging in HeLa cells\",\n      \"pmids\": [\"21586568\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological context distinguishing Rab5 versus Rab31 usage unclear\", \"CD-MPR cargo consequence (e.g., lysosomal enzyme sorting) not measured\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Placed RIN3 in a receptor signaling pathway, showing it acts downstream of KIT/SCF as a Rab5-GEF and negatively regulates KIT internalization and mast cell migration.\",\n      \"evidence\": \"RIN3 knockdown/overexpression, GTP-Rab5 pull-down, KIT internalization and migration assays in mast cells\",\n      \"pmids\": [\"23185384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking RIN3-BIN2 dissociation to KIT trafficking not fully resolved\", \"Whether Rab31 contributes in this context untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Resolved the molecular basis of RIN3 adaptor recruitment, mapping two proline-rich epitopes to CD2AP SH3-1/SH3-2 at atomic resolution and showing RIN3 recruits CD2AP to RAB5a endosomes.\",\n      \"evidence\": \"Peptide array, Co-IP, ITC, X-ray crystallography (1.65 Å, 1.11 Å), and co-localization\",\n      \"pmids\": [\"26296892\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of CD2AP recruitment in trafficking not established\", \"Competition between CD2AP and BIN1 for RIN3 not examined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Linked RIN3 to neurodegeneration-relevant trafficking, showing RIN3 recruits BIN1 and CD2AP to endosomes and promotes APP cleavage and Tau phosphorylation through a Rab5-dependent pathway.\",\n      \"evidence\": \"Co-IP, MS interactomics, Y2H, APP CTF western, axonal transport imaging, and dominant-negative Rab5 rescue in PC12 and primary BFCNs\",\n      \"pmids\": [\"32552912\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct mechanism connecting Rab5 activation to APP processing not detailed\", \"In vivo relevance to disease not yet tested at this stage\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined isoform-specific control of amyloidogenesis, showing RIN3 sequesters neuronal BIN1V1 to delay APP (not BACE1) endocytosis, spatially separating the two and reducing Aβ generation.\",\n      \"evidence\": \"Confocal microscopy, FACS enrichment, Aβ ELISA, biotinylated APP internalization, and APP processing western blots\",\n      \"pmids\": [\"35241726\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise CLAP-domain contribution to sequestration not biochemically proven\", \"Generalizability beyond the studied neuronal model unaddressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided in vivo loss-of-function evidence that RIN3 negatively regulates bone resorption, showing Rin3 knockout increases trabecular bone mass via reduced osteoclast surface.\",\n      \"evidence\": \"Constitutive Rin3 knockout mice, micro-CT, and bone histomorphometry\",\n      \"pmids\": [\"33725152\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism in osteoclasts not defined\", \"Whether the effect is cell-autonomous to osteoclasts not resolved\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Established BIN1 as the critical brake on RIN3 and connected RIN3 to familial Alzheimer's disease, showing that disrupting BIN1-RIN3 binding by knockout or AD missense mutations causes RAB5 hyperactivation and endosomal enlargement.\",\n      \"evidence\": \"Rin3 knockout mice, CRISPR-edited human iPSC-derived neurons, RAB5 activation assays, endosome size quantification, and transcriptomics\",\n      \"pmids\": [\"41604486\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of how BIN1 binding suppresses GEF activity not resolved\", \"Downstream consequences of RAB5 hyperactivation on neuronal survival not fully mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How RIN3's distinct interactions and GEF activities (Rab5 vs Rab31; BIN1 vs CD2AP vs amphiphysin) are coordinately switched across cell types and signaling states remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No integrated structural model of the autoinhibited versus activated full-length protein\", \"Identity of the physiological kinase activating RIN3 unknown\", \"Quantitative rules governing partner selection at the endosome undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005085\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 3, 5]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [1, 6, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [6, 7, 9, 10]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [0, 3, 5]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 5]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 9, 10]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BIN1\", \"CD2AP\", \"RAB5\", \"RAB31\", \"AMPH2\", \"KIT\", \"RAS\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}